Trial
NCT01796470
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Gilead Sciences
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
Entospletinib
Why stopped
Study was terminated due to safety measures.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-02